|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
WHO00788804X |
| 003 |
DE-627 |
| 005 |
20230425175702.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
210913s2021 xx |||||o 00| ||eng c |
| 035 |
|
|
|a (DE-627)WHO00788804X
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)EUCTR2021-001028-16-ES
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)EARLY-DEX
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 245 |
1 |
0 |
|a DEXamethasone EARLY administration in hospitalized patients with Covid-19 pneumonia
|b DEXamethasone EARLY administration in hospitalized patients with Covid-19 pneumonia and high risk of developing acute respiratory distress syndrome - EARLY-DEX Covid-19
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 01-09-2021, Last updated: 2022-11-24
|
| 650 |
|
4 |
|a Medical Condition: Hospitalized patients with Covid-19 pneumonia who do not require oxygen therapy on admission associated with at least two of the three following factors related with severe Covid-19: lactate dehydrogenase > 245 U/L, C-reactive protein > 100 mg/L and lymphocyte count < 800 cells/µL.;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
|
| 650 |
|
4 |
|a Study Type: Interventional
|
| 650 |
|
4 |
|a Phase: Phase 4
|
| 650 |
|
4 |
|a Recruitment Status: Authorised-recruitment may be ongoing or finished
|
| 650 |
|
4 |
|a 610
|
| 773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2021) vom: 07. Sept.
|
| 773 |
1 |
8 |
|g year:2021
|g day:07
|g month:09
|
| 856 |
4 |
0 |
|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-001028-16
|z kostenfrei
|3 Volltext
|
| 912 |
|
|
|a GBV_CTG
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|j 2021
|b 07
|c 09
|
Klinische Studie